EGFR and colorectal carcinoma: Hu et al. reported that the anti-HGF mAb ficlatuzumab significantly inhibited the c-MET activation and rescued the capacity of cetuximab to inhibit the phosphorylation of EGFR in cetuximab-resistant CRC cell lines LM1215, SW48, and DiFi (Hu et al., 2016).